Huntington's disease (HD): Degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem

Brain Pathology

Volumn 24, Issue 3, 2014, Pages 247-260

  Rüb, Udo ^a   Hentschel, Matthias ^a   Stratmann, Katharina ^a   Brunt, Ewout ^b   Heinsen, Helmut ^c   Seidel, Kay ^a   Bouzrou, Mohamed ^a   Auburger, Georg ^a   Paulson, Henry ^d   Vonsattel, Jean Paul ^e   Lange, Herwig ^f   Korf, Horst Werner ^a   Den Dunnen, Wilfred ^g  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

axonal inclusions; brainstem; Huntington's disease; neurodegeneration; pathoanatomy; polyglutamine diseases

Indexed keywords

POLYGLUTAMINE; HTT PROTEIN, HUMAN; NERVE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN; UBIQUITIN;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN STEM; CELL NUCLEUS INCLUSION BODY; CEREBELLUM; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOREACTIVITY; INFERIOR OLIVE; INTERPOSITUS NUCLEUS; MALE; NERVE DEGENERATION; NERVE FIBER; NEUROPATHOLOGY; OCULOMOTOR NERVE DISEASE; OCULOMOTOR SYSTEM; PATHOLOGICAL ANATOMY; PONS RETICULAR FORMATION; PONTINE NUCLEUS; SUBSTANTIA NIGRA; SUPERIOR OLIVARY NUCLEUS; SYMPTOM; VERY ELDERLY; VESTIBULAR NUCLEUS; VESTIBULAR SYSTEM; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; TRINUCLEOTIDE REPEAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; AXONS; BRAIN STEM; FEMALE; HUMANS; HUNTINGTON DISEASE; INTRANUCLEAR INCLUSION BODIES; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; TRINUCLEOTIDE REPEATS; UBIQUITIN;

EID: 84898548010     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12115     Document Type: Article

References (86)

1. Arrasate M, Finkbeiner S, (2012) Protein aggregates in Huntington's disease. Exp Neurol 238: 1-11.
2. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA, (1998) Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4: 387-397.
3. Braak H, Braak E, (1992) Allocortical involvement in Huntington's disease. Neuropathol Appl Neurobiol 18: 539-547.
4. Braak H, Rüb U, Del Tredici K, (2003) Involvement of precerebellar nuclei in multiple system atrophy. Neuropathol Appl Neurobiol 29: 60-76.
5. Bruyn GW, Bots GTAM, Dom R, (1979) Huntington's chorea: current neuropathological status. Adv Neurol 23: 83-93.
6. Busse ME, Wiles CM, Rosser AE, (2009) Mobility and falls in people with Huntington's disease. J Neurol Neurosurg Psychiatry 80: 88-90.
7. Büttner-Ennever JA, (2006) The extraocular motor nuclei: organization and functional neuroanatomy. Prog Brain Res 151: 95-125.
8. Büttner-Ennever JA, Gerrits NM, (2004) Vestibular system. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 1213-1240. Elsevier: San Diego.
9. Büttner-Ennever JA, Horn AKE, (2004) Reticular formation: eye movements, gaze, and blinks. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 479-510. Elsevier: San Diego.
10. Davies JE, Sarkar S, Rubinsztein DC, (2007) The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem 8 (Suppl. 1): S2.
11. De Vos KJ, Grierson AJ, Ackerley S, Miller CC, (2008) Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31: 151-173.
12. Den Dunnen WF, (2013) Neuropathological diagnostic considerations in hyperkinetic movement disorders. Front Neurol 4: 7.
13. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
14. Difiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N, (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
15. Dom R, Malfroid M, Baro F, (1976) Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology 26: 64-68.
16. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-392.
17. Gil JM, Rego AC, (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820.
18. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P, (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 301 (Pt 3): 871-877.
19. Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheux B, Hauw JJ, Trottier Y, et al (1998) Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 9: 1823-1826.
20. Grimbergen YA, Knol MJ, Bloem BR, Kremer BP, Roos RA, Munneke M, (2008) Falls and gait disturbances in Huntington's disease. Mov Disord 23: 970-976.
21. Gunawardena S, Goldstein LS, (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62: 46-51.
22. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19: 2522-2534.
23. Halliday G, (2004) Substantia nigra and locus coeruleus. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 449-463. Elsevier: San Diego.
24. Harper PS, (1992) The epidemiology of Huntington's disease. Hum Genet 89: 365-376.
25. Heinsen H, Rüb U, Bauer M, Ulmar G, Bethke B, Schüler M, et al (1999) Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 97: 613-622.
26. Heinsen H, Rüb U, Gangnus D, Jungkunz G, Bauer M, Ulmar G, et al (1996) Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol 91: 161-168.
27. Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D, et al (1994) Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 88: 320-333.
28. Hoche F, Seidel K, Brunt ER, Auburger G, Schöls L, Bürk K, et al (2008) Involvement of the auditory brainstem system in spinocerebellar ataxia type 2 (SCA2), type 3 (SCA3) and type 7 (SCA7). Neuropathol Appl Neurobiol 34: 479-491.
29. Horn AK, (2006) The reticular formation. Prog Brain Res 151: 127-155.
30. Huang Q, Figueiredo-Pereira ME, (2010) Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 15: 1292-1311.
31. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, et al (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412: 191-209.
32. Koeppen AH, (1989) The nucleus pontis centralis caudalis in Huntington's disease. J Neurol Sci 91: 129-141.
33. Koutcherov Y, Huang XF, Halliday G, Paxinos G, (2004) Organization of human brain stem nuclei. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 267-320. Elsevier: San Diego.
34. Kremer B, Weber B, Hayden MR, (1992) New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease. Brain Pathol 2: 321-335.
35. Kremer HP, Roos RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA, (1991) The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 132: 101-104.
36. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, et al (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46: 842-849.
37. Kuusisto E, Kauppinen T, Alafuzoff I, (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34: 169-180.
38. Kuusisto E, Salminen A, Alafuzoff I, (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12: 2085-2090.
39. Lange H, Thorner G, Hopf A, Schroder KF, (1976) Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 28: 401-425.
40. Lange HW, (1981) Quantitative changes of telencephalon, diencephalon, and mesencephalon in Huntington's chorea, postencephalitic, and idiopathic Parkinsonism. Verh Anat Ges 73: 923-925.
41. Lange HW, Aulich A, (1986) Die Hirnatrophie bei der Huntingtonschen Krankheit. In: Die Huntingtonsche Krankheit, 1st edn., H Oepen, (ed.), pp. 25-41. Hippokrates Verlag: Stuttgart.
42. Lasker AG, Zee DS, (1997) Ocular motor abnormalities in Huntington's disease. Vision Res 37: 3639-3645.
43. Lastres-Becker I, Rüb U, Auburger G, (2008) Spinocerebellar ataxia 2 (SCA2). Cerebellum 7: 115-124.
44. Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA, (1983) Abnormal ocular motor control in Huntington's disease. Neurology 33: 1268-1275.
45. Leigh RJ, Parhad IM, Clark AW, Buettner-Ennever JA, Folstein SE, (1985) Brainstem findings in Huntington's disease. Possible mechanisms for slow vertical saccades. J Neurol Sci 71: 247-256.
46. Li JY, Conforti L, (2012) Axonopathy in Huntington's disease. Exp Neurol 246: 62-72.
47. Maat-Schieman M, Roos R, Losekoot M, Dorsman J, Welling-Graafland C, Hegeman-Kleinn I, et al (2007) Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol 17: 31-37.
48. Maat-Schieman ML, Dorsman JC, Smoor MA, Siesling S, van Duinen SG, Verschuuren JJ, et al (1999) Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 58: 129-137.
49. Margolis RL, Ross CA, (2003) Diagnosis of Huntington disease. Clin Chem 49: 1726-1732.
50. Moore JK, Linthicum FH, (2004) Auditory system. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 1241-1279. Elsevier: San Diego.
51. Myers RH, (2004) Huntington's disease genetics. NeuroRx 1: 255-262.
52. Oyanagi K, Takeda S, Takahashi H, Ohama E, Ikuta F, (1989) A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 26: 13-19.
53. Paulus W, Jellinger K, (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755.
54. Riess O, Rüb U, Pastore A, Bauer P, Schöls L, (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7: 125-137.
55. Rubinsztein DC, (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443: 780-786.
56. Rubinsztein DC, Carmichael J, (2003) Huntington's disease: molecular basis of neurodegeneration. Expert Rev Mol Med 5: 1-21.
57. Rüb U, Brunt ER, Deller T, (2008) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21: 111-116.
58. Rüb U, Brunt ER, Gierga K, Schultz C, Paulson H, de Vos RA, Braak H, (2003) The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat 25: 115-127.
59. Rüb U, Brunt ER, Gierga K, Seidel K, Schultz C, Schöls L, et al (2005) Spinocerebellar ataxia type 7 (SCA7): first report of a systematic neuropathological study of the brain of a patient with a very short expanded CAG-repeat. Brain Pathol 15: 287-295.
60. Rüb U, Brunt ER, de Vos RA, Del Turco D, Del Tredici K, Gierga K, et al (2004) Degeneration of the central vestibular system in spinocerebellar ataxia type 3 (SCA3) patients and its possible clinical significance. Neuropathol Appl Neurobiol 30: 402-414.
61. Rüb U, Bürk K, Timmann D, den Dunnen W, Seidel K, Brunt E, et al (2012) Spinocerebellar ataxia type 1 (SCA1): new pathoanatomical and clinico-pathological insights. Neuropathol Appl Neurobiol 38: 665-680.
62. Rüb U, Heinsen H, Brunt ER, Landwehrmeyer B, Den Dunnen WF, Gierga K, Deller T, (2009) The human premotor oculomotor brainstem system-can it help to understand oculomotor symptoms in Huntington's disease? Neuropathol Appl Neurobiol 35: 4-15.
63. Rüb U, Hoche F, Brunt ER, Heinsen H, Seidel K, Del Turco D, et al (2013) Degeneration of the cerebellum in Huntington's Disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol 23: 165-177.
64. Rüb U, Jen JC, Braak H, Deller T, (2008) Functional neuroanatomy of the human premotor oculomotor brainstem nuclei: insights from postmortem and advanced in vivo imaging studies. Exp Brain Res 187: 167-180.
65. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, Difiglia M, (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58: 165-173.
66. Schulte J, Littleton JT, (2011) The biological function of the Huntingtin protein and its relevance to Huntington's disease pathology. Curr Trends Neurol 5: 65-78.
67. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW, (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24: 8055-8068.
68. Seidel K, Brunt ER, de Vos RA, Dijk F, van der Want HJ, Rüb U, Den Dunnen WF, (2009) The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia type 6. Clin Neuropathol 28: 344-349.
69. Seidel K, Den Dunnen WF, Schultz C, Paulson H, Frank S, de Vos RA, et al (2010) Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 120: 449-460.
70. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rüb U, (2012) Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124: 1-21.
71. Shaw G, Osborn M, Weber K, (1981) An immunofluorescence microscopical study of the neurofilament triplet proteins, vimentin and glial fibrillary acidic protein within the adult rat brain. Eur J Cell Biol 26: 68-82.
72. Shoulson I, Young AB, (2011) Milestones in Huntington disease. Mov Disord 26: 1127-1133.
73. Sieradzan KA, Mann DM, (2001) The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol 27: 1-21.
74. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM, (1999) Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156: 92-99.
75. Smithson KG, MacVicar BA, Hatton GI, (1983) Polyethylene glycol embedding: a technique compatible with immunocytochemistry, enzyme histochemistry, histofluorescence and intracellular staining. J Neurosci Methods 7: 27-41.
76. The Huntington's disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
77. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, et al (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10: 104-110.
78. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, et al (1995) Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378: 403-406.
79. Truant R, Atwal R, Burtnik A, (2006) Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Biochem Cell Biol 84: 912-917.
80. Valera AG, Diaz-Hernandez M, Hernandez F, Ortega Z, Lucas JJ, (2005) The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 11: 583-594.
81. Vonsattel JP, (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115: 55-69.
82. Vonsattel JP, Difiglia M, (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369-384.
83. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr, (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577.
84. Voogd J, (2004) Cerebellum and precerebellar nuclei. In: The Human Nervous System, 2nd edn., G Paxinos, JK Mai, (eds), pp. 321-392. Elsevier: San Diego.
85. Walker FO, (2007a) Huntington's disease. Semin Neurol 27: 143-150.
86. Walker FO, (2007b) Huntington's disease. Lancet 369: 218-228.